Indirect Treatment Comparison of 48-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting Every 2 Months to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Suppressed HIV-1-Infected Participants
IDwk 2021 Sept 29-Oct 3
Sonya J. Snedecor1, Melanie Schroeder2, Nicolas Van de Velde2
1OPEN Health, Bethesda, MD, United States; 2ViiV Healthcare, Brentford, United Kingdom
